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Some Salt with Your Statin, Professor?
Malcolm Macleod*
Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom
Abstract: We know that clinical trials sponsored by the
pharmaceutical industry are likely to exaggerate benefit
and minimise harms. But do these biases extend to their
sponsorship of non-human animal research? Using
systematic review and meta-analysis Bero and colleagues
show that, in the case of statins, things are a little more
complicated. While the conclusions of industry-sponsored
studies were indeed more enthusiastic than warranted by
their data, the data themselves painted a picture more
conservative than was seen in non-industry-sponsored
studies. This behaviour is consistent with maximising the
return on investment, seeking robust data before
embarking on a clinical trial, and, once that investment
has been made, making every effort to ‘‘prove’’ that the
drug is safe and effective if this is at all credible. The
findings suggest that there is something different about
industry-sponsored non-human animal research, perhaps
reflecting higher standards than is the case elsewhere.
Perhaps the academic community can learn something
from our colleagues in the commercial sector.
It is now pretty clear that, in clinical trials, sponsorship from the
pharmaceutical industry is associated with substantial and
important overstatement of how effective drugs are, and with
understatement of adverse effects [1]. Of course, these are average
effects, and so are insufficient to label the whole industry bad.
Nonetheless, there are many examples where industry has been
shown to seek to subvert rational interpretation of trial data to
influence guideline development and prescribing behaviour [2–4].
These examples lead to the reasonable conclusion that findings
from trials sponsored by the pharmaceutical industry need to taken
with more salt than is probably good for you.
What then of other research used to inform the drug
development process? What of the in vitro and in vivo non-
human research supported by industry, either in companies’ own
laboratories or that companies fund in contract research
organisations or in academic collaborations? Are the findings of
such studies credible? And how do those findings compare with
‘‘proper’’ research conducted by dispassionate academics?
These are important questions, but how could we find this stuff
out? In the same way that it would be difficult to conduct a
randomised controlled trial of the effect of living in Scotland on
your chance of having a stroke, it is difficult to do an experiment to
test whether the funding source for a study influences the outcome.
We have to rely on observational (rather than experimental)
research, and we need to be much more cautious in our approach
and in our conclusions.
Over the last few years there has been a big increase in the use
of such an observational approach to better understand the
strengths and weaknesses of different research domains. The
Cochrane Collaboration began as an attempt to give reliable
summaries of the effectiveness of treatments in human clinical
trials [5], but along the way the data collected have also allowed
investigation of whether studies with certain characteristics tended
to give overstatement or understatement of these summary
treatment effects [6]. The insights arising from this approach,
and the improvements in trial design that they have driven, are
just as important as the improved information to guide treatment
decisions. This approach has been used by others—notably Lisa
Bero, the senior author of the research article presented here—in a
series of important papers that identified the prevalence and
impact of funding bias in human research [7,8].
Those wishing to study, and to improve, other research domains
such as non-human animal research have been able shamelessly to
borrow from the experience of the Cochrane Collaboration. Using
a systematic approach to data retrieval we can assemble an
unbiased cohort of relevant studies, then observe associations
between different aspects of experimental design and the
magnitude of the effects reported. What we’re looking for are
design features that are consistently associated with either under-
or overestimation of biological effects.
Of course, meta-analyses of clinical trial data put together a
small number of large studies measuring a common treatment
effect, whereas in animal studies there is usually a large number of
small studies measuring different effects (dose, stage of illness,
different animals), which means the approach used has to be
adjusted slightly, but still, the approach has been fruitful.
For a large number of non-human animal disease models,
studies at risk of bias (for example, those without randomisation or
blinding) give larger estimates of treatment effects [9–13]; the
majority of studies are at risk of bias [9–14]; and journal impact
factor is no guarantee of low risk of bias [15]. These findings
influenced the development of reporting standards for stroke [16]
and non-human animal research more generally [17,18], and
these are beginning to make an impact.
One difficulty in using meta-analysis is in working out how to
combine different outcome measures, often from different animals.
A 0.1-mm increase in aortic arch atheroma is probably less
important in a Scot than it is in a mouse, so we need to transform
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data onto a common scale. In standardised mean difference
(SMD) meta-analysis, the effect is standardised to the observed
variance [19]. Because—in large studies at least—this variance is a
property of the biology being studied rather than of the scale being
used, it allows effects to be converted to a common scale. So, by
way of an example: in 2012 the variance of the monthly average
temperature across 258 weather stations in California was
12.55uF, or 6.98uC—from which we can calculate that 1uC is
the same as 1.80uF, or 0.14 standardised units, and so we have a
common scale.
While this approach is very useful in clinical meta-analyses
(where the large number of participants in each group allows a
precise estimate of the population variance), it becomes less useful
where group size is small, because here the observed variance is a
less precise estimate of the population variance. This introduces a
measurement error to the conversion between different scales.
Further, this observed variance represents a combination of
underlying biological variation in the phenomena being measured
and of variation arising from measurement error and from the way
the experiment was performed. Experiments with low measure-
ment error and good protocol compliance will therefore have
lower aggregate variance than those with high measurement error
and poor protocol compliance. Since the variance is the
denominator in the calculation of the size of differences between
groups, any given effect size will be artificially larger in studies with
low measurement error and experimental variability.
The demonstration that experiments with low methodological
quality can give inflated estimates of treatments effects, and that
most experiments appear to be of low methodological quality,
leads to the question of who might be the worst offenders. Since
clinical trials sponsored by the pharmaceutical industry seem to be
at greater risk of bias than others, a lazy assumption might be that
their non-human animal research is similarly confounded, as they
seek to rush compounds to market to maximise profitability.
However, a few straws in the wind hint this might not be the case.
One way companies identify drug targets is by reading what’s out
there in the literature and, if something looks interesting, seeking to
replicate the findings. Bayer scientists found inconsistencies in 43 of
65 studies when they tried to replicate them in-house [20]. Scientists
in the haematology and oncology departments at Amgen were able
to replicate findings in only six out of 53 publications identified as
‘‘landmark’’ studies [21]. When the ALS Therapy Development
Institute tried to replicate published findings of drug efficacy in the
superoxide dismutase mouse model of motor neuron disease
(amyotrophic lateral sclerosis), not one of seven interventions
retained efficacy [22]. Implementation of good laboratory practice
standards is much more advanced in industry labs, and for some
types of experiments these standards are a legal requirement.
Indeed, a scientific researcher was recently jailed in Scotland for
research fraud [23]. So, could it be that industry-sponsored research
is actually more rigorous than academic research?
Taking the example of statin treatments for atheroma, David
Krauth, Andrew Anglemyer, Rose Philipps, and Lisa Bero address
this issue head-on [24]. Using systematic review they identified
non-human animal studies describing the efficacy of statins. Their
methodology is secure, with an a priori analysis plan, clear
inclusion and exclusion criteria, and duplicate extraction of key
variables from identified publications. They found low levels of
reporting of measures known to reduce the risk of bias, with
blinded assessment of outcome reported in only 22 of 49 studies,
and no studies reporting full randomisation or a sample size
calculation. Reassuringly, the quality of reporting seems to have
improved somewhat since publication of the ARRIVE guidelines
in 2010. However, there is still clearly a long way to go.
On the question of the influence of the study sponsor, Bero and
colleagues identified 19 studies sponsored in whole or part by
industry, 28 sponsored by non-industry sources, and 16 with no
statement of sponsorship or a statement of no sponsorship.
Focussing on those studies where sponsorship status was known,
they found that the results of nine of 19 industry-sponsored studies
(43%) and 18 of 28 non-industry-sponsored studies (72%)
supported the efficacy of statins. This finding was confirmed in a
subset of 38 studies with sufficient data to allow meta-analysis;
statins were reported to improve outcome by 0.73 SMD units in
industry-sponsored studies, while in studies with other sponsorship
the improvement was 1.99 SMD units. This difference is highly
significant—I calculate an excess of efficacy in non-industry-
sponsored studies of 173% (95% confidence interval 52% to
293%). Put simply, studies with non-industry sponsorship report
that statins are almost three times more effective than do industry-
sponsored studies.
As interesting, however, is the analysis of the interpretation
placed on the findings in each of the included studies. Of 19
industry-sponsored studies, the conclusion of 18 favoured the use
of statins (95%), while of 28 non-industry-sponsored studies, only
21 did so (75%). This is striking for two reasons: first, in both
cohorts the conclusion appears to be more enthusiastic than the
findings presented, and second, this phenomenon appears to be
much more marked in studies with industry sponsorship.
So what’s going on? Of course, these observed differences may
be due to some other, unmeasured difference between the
contributing studies, but the analyses were prespecified and such
a confound appears unlikely. If industry-sponsored studies were of
consistently larger variance, then the effect sizes observed would
appear smaller in SMD units, but there is no reason to suspect that
this was the case here.
It does therefore appear that findings from research sponsored
by industry are more conservative than those sponsored by non-
industry sources, but the interpretation of those data is, in contrast,
less conservative. Why might this be?
In a series of univariate analyses the authors examined the
impact of three factors—randomisation, blinding, and accounting
for all animals—that might increase the risk of bias. Even when
these were taken into account, non-industry-sponsored studies
gave significantly higher estimates of efficacy, implying that some
other factors were responsible. This might happen if ‘‘randomisa-
tion’’ and ‘‘blinding’’ meant different things in industry-sponsored
studies, or through the impact of some other, unmeasured risk of
bias, or through some gestalt of industry-sponsored studies that is
not described by the variables tested. Alternatively, academic
studies exploring pathophysiology might chose circumstances that
maximise the observed effect size, to give greater statistical power
to experiments testing inhibition of those effects.
In my view it is likely that the impact of approaches to research
management and the regulatory environment that apply to some
parts of industry—particularly standards for internal reporting—
extends to most of the non-human animal research activity with
which they are involved, whether or not it is performed in-house.
That is, non-human animal work sponsored by industry is likely to
be performed and reported to a higher quality, and to be at lower
risk of bias, than work sponsored by others. This would explain the
difficulty industry has in replicating the results of research
conducted in academic labs. However, the interpretation, or
‘‘spin’’, with which industry-sponsored work is presented does
appear to be an issue, with exaggeration of the conclusions to
favour the drug being tested.
This makes sense—for industry there is a clear financial interest
in being absolutely secure in the non-human animal data for a
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compound before embarking on a clinical trial, so there is a real
motivation to get the preclinical data as good as they can be.
Clinical trials are expensive, and so it is worth investing much time
and effort, and perhaps even funding multicentre ‘‘phase 3’’
animal studies [25–27], to maximise the prospects for success. But
when that money has been spent (and for statins it largely has
been), the motivation is to present an analysis of the available data
that is most supportive for clinical use. So, if a drug is a turkey, try
to find that out before spending a fortune taking it to clinical
trial—and if it’s too late for that, try to convince everyone that the
non-human animal and clinical trial data supporting an efficacy
for Meleagris gallopavo (commonly known as the wild turkey) are
more convincing than they might at first appear.
In contrast, academic researchers are rewarded not for the
marathon but for the sprint—for a high-impact publication
describing a part of the jigsaw, not for the body of work that
shows the whole picture. To them, substantial efficacy in a single
study is, in some respects, an end rather than a beginning.
Bero and colleagues have made an important contribution; their
findings suggest that academic researchers might learn good
practice in the management, conduct, and reporting of non-
human animal research from colleagues in industry, and reinforces
the importance for readers of research reports to focus on methods
and data rather than on abstracts and conclusions.
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